Cardiovascular and cerebrovascular diseases (CVD) encompass a range of conditions affecting the heart, brain, and blood vessels, including coronary heart disease, hypertension, and stroke. In recent years, there has been growing evidence highlighting the significant role of non-coding RNAs (ncRNAs) in the development and progression of cardiovascular diseases. Among the various types of ncRNAs, long-stranded non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) have emerged as prominent players in cardiovascular research. Advancements in technology and in-depth research have revealed that ncRNAs and circRNAs exert regulatory effects on the biological functions of the cardiovascular system through various pathways. For instance, they can modulate the proliferation, migration, and apoptosis of vascular endothelial cells, as well as regulate cardiac muscle contraction and cardiomyocyte apoptosis. Additionally, ncRNAs and circRNAs can influence downstream targets and pathways involved in cardiovascular diseases. The exploration of ncRNAs and circRNAs in cardiovascular research has opened up new avenues for the diagnosis and treatment of CVDs. By understanding the intricate regulatory mechanisms mediated by these non-coding RNAs, researchers have gained valuable insights into the pathogenesis of cardiovascular diseases and identified potential therapeutic targets. Consequently, these studies have provided novel ideas and approaches for the diagnosis, prevention, and management of CVDs.
1. Li, J., et al., Atherosclerosis Vascular Endothelial Secretion Dysfunction and Smooth Muscle Cell Proliferation. Journal of Healthcare Engineering, 2022. 2022.
2. Cao, Z.-Q., X. Yu, and P. Leng, Research progress on the role of gal-3 in cardio/cerebrovascular diseases. Biomedicine & Pharmacotherapy, 2021. 133: p. 111066.
3. Liang, J., et al., Discussion on Treatment of Atherosclerosis From Liver Theory. Journal of Liaoning University of Traditional Chinese Medicine, 2018.
4. Li, M. and J. Zhang, Circulating MicroRNAs: potential and emerging biomarkers for diagnosis of cardiovascular and cerebrovascular diseases. BioMed Research International, 2015. 2015.
5. Barnes, R.P., J.C.A. Lacson, and H. Bahrami, HIV infection and risk of cardiovascular diseases beyond coronary artery disease. Current atherosclerosis reports, 2017. 19: p. 1-9.
6. Asri, A.K., et al., Global greenness in relation to reducing the burden of cardiovascular diseases: ischemic heart disease and stroke. Environmental Research Letters, 2020. 15(12): p. 124003.
7. Piché, M.-E., A. Tchernof, and J.-P. Després, Obesity phenotypes, diabetes, and cardiovascular diseases. Circulation research, 2020. 126(11): p. 1477-1500.
8. Riegel, B., et al., Self‐care for the prevention and management of cardiovascular disease and stroke: A scientific statement for healthcare professionals from the American Heart Association. Journal of the American Heart Association, 2017. 6(9): p. e006997.
9. Eddy, S.R., Non–coding RNA genes and the modern RNA world. Nature Reviews Genetics, 2001. 2(12): p. 919-929.
10. Taft, R.J., et al., Non‐coding RNAs: regulators of disease. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland, 2010. 220(2): p. 126-139.
11. Li, C., et al., Roles and mechanisms of exosomal non-coding RNAs in human health and diseases. Signal transduction and targeted therapy, 2021. 6(1): p. 383.
12. Liu, S. and W. Chong, Roles of LncRNAs in regulating mitochondrial dysfunction in septic cardiomyopathy. Frontiers in Immunology, 2021. 12: p. 802085.
13. Wang, J., et al., The role of lncRNAs in osteogenic differentiation of bone marrow mesenchymal stem cells. Current stem cell research & therapy, 2020. 15(3): p. 243-249.
14. Ballantyne, M.D., R.A. McDonald, and A.H. Baker, lncRNA/MicroRNA interactions in the vasculature. Clinical Pharmacology & Therapeutics, 2016. 99(5): p. 494-501.
15. Tang, X.J., W. Wang, and S.S. Hann, Interactions among lncRNAs, miRNAs and mRNA in colorectal cancer. Biochimie, 2019. 163: p. 58-72.
16. Villegas, V.E. and P.G. Zaphiropoulos, Neighboring gene regulation by antisense long non-coding RNAs. International journal of molecular sciences, 2015. 16(2): p. 3251-3266.
17. Chang, Z., et al., Epigenetic mechanisms of drug resistance in fungi. Fungal Genetics and Biology, 2019. 132: p. 103253.
18. Statello, L., et al., Gene regulation by long non-coding RNAs and its biological functions. Nature reviews Molecular cell biology, 2021. 22(2): p. 96-118.
19. Xu, J.-z., J.-l. Zhang, and W.-g. Zhang, Antisense RNA: the new favorite in genetic research. Journal of Zhejiang University-SCIENCE B, 2018. 19(10): p. 739-749.
20. Carlevaro-Fita, J., et al., Cytoplasmic long noncoding RNAs are frequently bound to and degraded at ribosomes in human cells. Rna, 2016. 22(6): p. 867-882.
21. Archer, K., et al., Long non-coding RNAs as master regulators in cardiovascular diseases. International journal of molecular sciences, 2015. 16(10): p. 23651-23667.
22. Lorenzen, J.M. and T. Thum, Long noncoding RNAs in kidney and cardiovascular diseases. Nature Reviews Nephrology, 2016. 12(6): p. 360-373.
23. Hou, K., et al., Prediction and identification of sulfur-responding circular RNA in Chlamydomonas reinhardtii. Shenzhen Daxue Xuebao (ligong Ban), 2020. 37(3): p. 221-223.
24. Qin, M., G. Wei, and X. Sun, Circ-UBR5: an exonic circular RNA and novel small nuclear RNA involved in RNA splicing. Biochemical and biophysical research communications, 2018. 503(2): p. 1027-1034.
25. Verduci, L., et al., CircRNAs: role in human diseases and potential use as biomarkers. Cell death & disease, 2021. 12(5): p. 468.
26. Guil, S. and M. Esteller, RNA–RNA interactions in gene regulation: the coding and noncoding players. Trends in biochemical sciences, 2015. 40(5): p. 248-256.
27. Liu, G., et al., E2F3 promotes liver cancer progression under the regulation of circ-PRKAR1B. Molecular Therapy-Nucleic Acids, 2021. 26: p. 104-113.
28. Shen, B. and K. Sun, Exosomal circular RNAs: A new frontier in the metastasis of digestive system tumors. Oncology Letters, 2021. 22(6): p. 1-13.
29. Mahmoudi, E., et al., Depolarization-associated CircRNA regulate neural gene expression and in some cases may function as templates for translation. Cells, 2019. 9(1): p. 25.
30. Su, Q. and X. Lv, Revealing new landscape of cardiovascular disease through circular RNA-miRNA-mRNA axis. Genomics, 2020. 112(2): p. 1680-1685.
31. Tang, Y., et al., Circular RNA in cardiovascular disease: Expression, mechanisms and clinical prospects. Journal of cellular and molecular medicine, 2021. 25(4): p. 1817-1824.
32. Gong, X., et al., Circular RNA circEsyt2 regulates vascular smooth muscle cell remodeling via splicing regulation. The Journal of Clinical Investigation, 2021. 131(24).
33. Wan, H., et al., CircRNAs in diabetic cardiomyopathy. Clinica Chimica Acta, 2021. 517: p. 127-132.
34. Zhang, W., et al., Non‐coding RNA involvement in the pathogenesis of diabetic cardiomyopathy. Journal of Cellular and Molecular Medicine, 2019. 23(9): p. 5859-5867.
35. Yu, H., et al., Circ_0003423 Alleviates ox-LDL-Induced Human Brain Microvascular Endothelial Cell Injury via the miR-589-5p/TET2 Network. Neurochemical Research, 2021: p. 1-12.
36. Xie, Q., et al., What is the impact of human umbilical cord mesenchymal stem cell transplantation on clinical treatment? Stem cell research & therapy, 2020. 11: p. 1-13.
37. Tang, N., et al., Noncoding RNA s as therapeutic targets in atherosclerosis with diabetes mellitus. Cardiovascular therapeutics, 2018. 36(4): p. e12436.
38. Wu, M., M. Xun, and Y. Chen, Circular RNAs: regulators of vascular smooth muscle cells in cardiovascular diseases. Journal of Molecular Medicine, 2022. 100(4): p. 519-535.
39. Maiuolo, J., et al., The contribution of gut microbiota and endothelial dysfunction in the development of arterial hypertension in animal models and in humans. International Journal of Molecular Sciences, 2022. 23(7): p. 3698.
40. Vaughan, C.J. and N. Delanty, Hypertensive emergencies. The Lancet, 2000. 356(9227): p. 411-417.
41. Lackland, D.T. and M.A. Weber, Global burden of cardiovascular disease and stroke: hypertension at the core. Canadian Journal of Cardiology, 2015. 31(5): p. 569-571.
42. Aburto, N.J., et al., Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. Bmj, 2013. 346.
43. Gomes, C.P., et al., The function and therapeutic potential of long non-coding RNAs in cardiovascular development and disease. Molecular Therapy-Nucleic Acids, 2017. 8: p. 494-507.
44. Han, Y., et al., Role of long non-coding RNAs in pulmonary arterial hypertension. Cells, 2021. 10(8): p. 1892.
45. Lei, S., et al., LncRNA-SMILR modulates RhoA/ROCK signaling by targeting miR-141 to regulate vascular remodeling in pulmonary arterial hypertension. American Journal of Physiology-Heart and Circulatory Physiology, 2020. 319(2): p. H377-H391.
46. Wang, Y.-N.-Z., et al., Long noncoding RNA-GAS5: a novel regulator of hypertension-induced vascular remodeling. Hypertension, 2016. 68(3): p. 736-748.
47. Esawy, M.M., et al., LncRNA-GAS5 and β-Catenin as Independent Predictors of Asymptomatic Organ Damage in Nondiabetic Hypertensive Patients. ACS Omega, 2023.
48. Huang, K., et al., Effects of CDKN2B‐AS1 polymorphisms on the susceptibility to coronary heart disease. Molecular genetics & genomic medicine, 2019. 7(11): p. e955.
49. Bayoglu, B., et al., Polymorphisms in the long non-coding RNA CDKN2B-AS1 may contribute to higher systolic blood pressure levels in hypertensive patients. Clinical biochemistry, 2016. 49(10-11): p. 821-827.
50. Xu, S.-L., et al., Circular RNAs Regulate Vascular Remodelling in Pulmonary Hypertension. Disease Markers, 2022. 2022.
51. Zaiou, M., Circular RNAs in hypertension: challenges and clinical promise. Hypertension Research, 2019. 42(11): p. 1653-1663.
52. Ali, M.K., et al., The role of circular RNAs in pulmonary hypertension. European Respiratory Journal, 2022. 60(6).
53. Chen, M., et al., Circ_0000284: A risk factor and potential biomarker for prehypertension and hypertension. Hypertension Research, 2022: p. 1-10.
54. Tao, Z., et al., Hsa_circ_0037897 may be a risk factor for essential hypertension via hsa-miR-145-5p. Clinical and Experimental Hypertension, 2021. 43(3): p. 281-286.
55. Zhang, Z., et al., Circulating circular RNAs as biomarkers for the diagnosis of essential hypertension with carotid plaque. Clinical and Experimental Hypertension, 2022. 44(7): p. 601-609.
56. Prestes, P.R., et al., A guide to the short, long and circular RNAs in hypertension and cardiovascular disease. International Journal of Molecular Sciences, 2020. 21(10): p. 3666.
57. Liu, L., et al., Microarray profiling of circular RNA identifies hsa_circ_0126991 as a potential risk factor for essential hypertension. Cytogenetic and Genome Research, 2019. 157(4): p. 203-212.
58. Lin, F., et al., Advances in research on the circRNA-miRNA-mRNA network in coronary heart disease treated with traditional Chinese medicine. Evidence-Based Complementary and Alternative Medicine, 2020. 2020: p. 1-10.
59. Wang, Q., et al., Circular RNAs in pulmonary hypertension: Emerging biological concepts and potential mechanism. Animal Models and Experimental Medicine, 2022. 5(1): p. 38-47.
60. Zou, H. and Q. Mao, Circ_0037078 promotes trophoblast cell proliferation, migration, invasion and angiogenesis by miR‐576‐5p/IL1RAP axis. American Journal of Reproductive Immunology, 2022. 87(1): p. e13507.
61. Ambrose, J.A. and M. Singh, Pathophysiology of coronary artery disease leading to acute coronary syndromes. F1000prime reports, 2015. 7.
62. Newburger, J.W., et al., Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation, 2004. 110(17): p. 2747-2771.
63. Peng, J., Y. Zhan, and Y. Zong, METTL3-mediated LINC00657 promotes osteogenic differentiation of mesenchymal stem cells via miR-144-3p/BMPR1B axis. Cell and Tissue Research, 2022. 388(2): p. 301-312.
64. Guo, F., et al., The interplay of Lnc RNA ANRIL and miR‐181b on the inflammation‐relevant coronary artery disease through mediating NF‐κB signalling pathway. Journal of cellular and molecular medicine, 2018. 22(10): p. 5062-5075.
65. Huang, J., et al., LncRNA H19 rs4929984 variant is associated with coronary artery disease susceptibility in han chinese female population. Biochemical Genetics, 2021: p. 1-22.
66. Li, X., et al., lncRNA H19 alleviated myocardial I/RI via suppressing miR-877-3p/Bcl-2-mediated mitochondrial apoptosis. Molecular Therapy-Nucleic Acids, 2019. 17: p. 297-309.
67. Tan, J.-K., et al., LncRNA MIAT knockdown alleviates oxygen-glucose deprivation‑induced cardiomyocyte injury by regulating JAK2/STAT3 pathway via miR-181a-5p. Journal of Cardiology, 2021. 78(6): p. 586-597.
68. Kim, I.-J., et al., Association between HOTAIR lncRNA polymorphisms and coronary artery disease susceptibility. Journal of personalized medicine, 2021. 11(5): p. 375.
69. Wu, L., et al., LncRNA TONSL-AS1 participates in coronary artery disease by interacting with miR-197. Microvascular Research, 2021. 136: p. 104152.
70. Chen, J. and J. Dang, LncRNA CASC11 was downregulated in coronary artery disease and inhibits transforming growth factor-β 1. Journal of International Medical Research, 2020. 48(3): p. 0300060519889187.
71. Lu, Y., et al., Contribution of lncRNA CASC8, CASC11, and PVT1 genetic variants to the susceptibility of coronary heart disease. Journal of Cardiovascular Pharmacology, 2021. 77(6): p. 756-766.
72. Zhou, B. and J.W. Yu, A novel identified circular RNA, circRNA_010567, promotes myocardial fibrosis via suppressing miR-141 by targeting TGF-β1. Biochemical & Biophysical Research Communications, 2017: p. 769-775.
73. Tang, C.M., et al., CircRNA_000203 enhances the expression of fibrosis-associated genes by derepressing targets of miR-26b-5p, Col1a2 and CTGF, in cardiac fibroblasts. Scientific Reports, 2017. 7: p. 40342.
74. Zhengbiao, Z., et al., Circular RNA_HIPK3-Targeting miR-93-5p Regulates KLF9 Expression Level to Control Acute Kidney Injury. Computational and Mathematical Methods in Medicine, 2023. 2023.
75. Zhao, Z., et al., Peripheral blood circular RNA hsa_circ_0124644 can be used as a diagnostic biomarker of coronary artery disease. Scientific reports, 2017. 7(1): p. 39918.
76. Zhou, H., et al., Identification of circular RNA BTBD7_hsa_circ_0000563 as a novel biomarker for coronary artery disease and the functional discovery of BTBD7_hsa_circ_0000563 based on peripheral blood mononuclear cells: a case control study. Clinical Proteomics, 2022. 19(1): p. 37.
77. Zhang, S., et al., Regulatory roles of circular RNAs in coronary artery disease. Molecular Therapy-Nucleic Acids, 2020. 21: p. 172-179.
78. Van Wagoner, D.R. and J.M. Nerbonne, Molecular basis of electrical remodeling in atrial fibrillation. Journal of molecular and cellular cardiology, 2000. 32(6): p. 1101-1117.
79. Lourenço, A., et al. Left atrial ejection fraction estimation using SEGANet for fully automated segmentation of CINE MRI. in Statistical Atlases and Computational Models of the Heart. M&Ms and EMIDEC Challenges: 11th International Workshop, STACOM 2020, Held in Conjunction with MICCAI 2020, Lima, Peru, October 4, 2020, Revised Selected Papers 11. 2021. Springer.
80. Babapoor-Farrokhran, S., D. Gill, and R.T. Rasekhi, The role of long noncoding RNAs in atrial fibrillation. Heart Rhythm, 2020. 17(6): p. 1043-1049.
81. Wang, H., et al., Long non-coding RNA LICPAR regulates atrial fibrosis via TGF-β/Smad pathway in atrial fibrillation. Tissue and Cell, 2020. 67: p. 101440.
82. Wu, C., et al., Noncoding RNAs and Cardiac Fibrosis. Reviews in Cardiovascular Medicine, 2023. 24(2): p. 63.
83. Yang, P., et al., Long non‐coding RNA ANRIL interacts with microRNA‐34a and microRNA‐125a, and they all correlate with disease risk and severity of Parkinson's disease. Journal of Clinical Laboratory Analysis, 2022. 36(1): p. e24037.
84. Wang, W., et al., Research progress of LncRNAs in atrial fibrillation. Molecular Biotechnology, 2022. 64(7): p. 758-772.
85. Bektik, E., D.B. Cowan, and D.-Z. Wang, Long non-coding RNAs in atrial fibrillation: pluripotent stem cell-derived cardiomyocytes as a model system. International Journal of Molecular Sciences, 2020. 21(15): p. 5424.
86. Xie, L., et al., Identification of atrial fibrillation-related lncRNA based on bioinformatic analysis. Disease Markers, 2022. 2022.
87. Dai, H., et al., LncRNA nuclear-enriched abundant transcript 1 regulates atrial fibrosis via the miR-320/NPAS2 axis in atrial fibrillation. Frontiers in Pharmacology, 2021. 12: p. 647124.
88. Jiang, S., et al., The integrative regulatory network of circRNA, microRNA, and mRNA in atrial fibrillation. Frontiers in genetics, 2019. 10: p. 526.
89. Ruan, Z.-B., et al., Genome-wide analysis of circular RNA expression profiles in patients with atrial fibrillation. International journal of clinical and experimental pathology, 2020. 13(8): p. 1933.
90. Zhang, L., et al., CircCAMTA1 facilitates atrial fibrosis by regulating the miR-214-3p/TGFBR1 axis in atrial fibrillation. Journal of Molecular Histology, 2022: p. 1-11.
91. Gao, Y., et al., The potential regulatory role of hsa_circ_0004104 in the persistency of atrial fibrillation by promoting cardiac fibrosis via TGF-β pathway. BMC cardiovascular disorders, 2021. 21: p. 1-11.
92. Zhang, P.-P., J. Sun, and W. Li, Genome-wide profiling reveals atrial fibrillation-related circular RNAs in atrial appendages. Gene, 2020. 728: p. 144286.
93. Khan, M.S., et al., RNAs and gene expression predicting postoperative atrial fibrillation in cardiac surgery patients undergoing coronary artery bypass grafting. Journal of Clinical Medicine, 2020. 9(4): p. 1139.
94. Zhang, Y., et al., Characterization of circRNA‑associated ceRNA networks in patients with nonvalvular persistent atrial fibrillation. Molecular Medicine Reports, 2019. 19(1): p. 638-650.
95. Chen, Y., et al., Analysis of infiltrated immune cells in left atriums from patients with atrial fibrillation and identification of circRNA biomarkers for postoperative atrial fibrillation. Frontiers in Genetics, 2022. 13.
96. Kemp, C.D. and J.V. Conte, The pathophysiology of heart failure. Cardiovascular Pathology, 2012. 21(5): p. 365-371.
97. Tresch, D.D., Clinical manifestations, diagnostic assessment, and etiology of heart failure in elderly patients. Clinics in geriatric medicine, 2000. 16(3): p. 445-456.
98. Ruys, T.P., et al., Heart failure in pregnant women with cardiac disease: data from the ROPAC. Heart, 2014. 100(3): p. 231-238.
99. Mann, D.L. and M. Chakinala, Heart failure: pathophysiology and diagnosis. Harrison, s. Principles of Internal Medicine, 2015. 20: p. 4383-402.
100. Edelmann, F., et al., Chronic heart failure. Deutsches Ärzteblatt International, 2018. 115(8): p. 124.
101. Ponikowski, P., et al., Heart failure: preventing disease and death worldwide. ESC heart failure, 2014. 1(1): p. 4-25.
102. Fang, Y., et al., Recent advances on the roles of LncRNAs in cardiovascular disease. Journal of Cellular and Molecular Medicine, 2020. 24(21): p. 12246-12257.
103. Han, D., Q. Gao, and F. Cao, Long noncoding RNAs (LncRNAs)—the dawning of a new treatment for cardiac hypertrophy and heart failure. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 2017. 1863(8): p. 2078-2084.
104. Greco, S., et al., Long noncoding RNA dysregulation in ischemic heart failure. Journal of translational medicine, 2016. 14: p. 1-14.
105. El Azzouzi, H., P.A. Doevendans, and J.P.G. Sluijter, Long non-coding RNAs in heart failure: an obvious lnc. Annals of Translational Medicine, 2016. 4(9).
106. Hu, H., et al., Knockdown of lncRNA MALAT1 attenuates acute myocardial infarction through miR-320-Pten axis. Biomedicine & Pharmacotherapy, 2018. 106: p. 738-746.
107. Gong, X., et al., Long noncoding RNA MALAT1 promotes cardiomyocyte apoptosis after myocardial infarction via targeting miR-144-3p. bioscience reports, 2019. 39(8).
108. Ge, Z., et al., Long noncoding RNA NEAT1 promotes cardiac fibrosis in heart failure through increased recruitment of EZH2 to the Smad7 promoter region. Journal of Translational Medicine, 2022. 20: p. 1-16.
109. Liu, N., et al., LncRNA LncHrt preserves cardiac metabolic homeostasis and heart function by modulating the LKB1-AMPK signaling pathway. Basic Research in Cardiology, 2021. 116(1): p. 48.
110. Sato, M., et al., The lncRNA Caren antagonizes heart failure by inactivating DNA damage response and activating mitochondrial biogenesis. Nature communications, 2021. 12(1): p. 2529.
111. Gu, Q., et al., LncRNA promoted inflammatory response in ischemic heart failure through regulation of miR-455-3p/TRAF6 axis. Inflammation Research, 2020. 69: p. 667-681.
112. Fu, Y. and H. Sun, Biogenesis, cellular effects, and biomarker value of circHIPK3. Cancer Cell International, 2021. 21(1): p. 256.
113. Wu, C., et al., The regulation mechanisms and clinical application of microRNAs in myocardial infarction: a review of the recent 5 years. Frontiers in Cardiovascular Medicine, 2022. 8: p. 2205.
114. Wang, L., et al., Circular RNAs in cardiovascular diseases. Circular RNAs: Biogenesis and Functions, 2018: p. 191-204.
115. Bär, C., S. Chatterjee, and T. Thum, Long noncoding RNAs in cardiovascular pathology, diagnosis, and therapy. Circulation, 2016. 134(19): p. 1484-1499.
116. Fan, X., et al., Circular RNAs in cardiovascular disease: an overview. BioMed research international, 2017. 2017.
117. Si, X., et al., circRNA Hipk3 induces cardiac regeneration after myocardial infarction in mice by binding to Notch1 and miR-133a. Molecular Therapy-Nucleic Acids, 2020. 21: p. 636-655.
118. Wen, Z.-J., et al., Emerging roles of circRNAs in the pathological process of myocardial infarction. Molecular Therapy-Nucleic Acids, 2021. 26: p. 828-848.
119. Wang, K., et al., A circular RNA protects the heart from pathological hypertrophy and heart failure by targeting miR-223. European heart journal, 2016. 37(33): p. 2602-2611.
120. Wang, P., et al., MiR-223 promotes cardiomyocyte apoptosis by inhibiting Foxo3a expression. Eur Rev Med Pharmacol Sci, 2018. 22(18): p. 6119-6126.
121. Yang, M., X. Wang, and T. Wang, Regulation of mitochondrial function by noncoding RNAs in heart failure and its application in diagnosis and treatment. Journal of Cardiovascular Pharmacology, 2021. 78(3): p. 377-387.
122. Xue, Q., et al., Functional roles and mechanisms of ginsenosides from Panax ginseng in atherosclerosis. Journal of ginseng research, 2021. 45(1): p. 22-31.
123. Wang, Y., et al., Long non-coding RNAs in coronary atherosclerosis. Life sciences, 2018. 211: p. 189-197.
124. Cheng, C., et al., CircRnas in atherosclerosis, with special emphasis on the spongy effect of circRnas on miRnas. Cell Cycle, 2022: p. 1-15.
125. Kang, L., et al., Identification of differently expressed mRNAs in atherosclerosis reveals CDK6 Is regulated by circHIPK3/miR-637 axis and promotes cell growth in human vascular smooth muscle cells. Frontiers in Genetics, 2021. 12: p. 596169.
126. Singh, D., V. Rai, and D.K. Agrawal, Non-Coding RNAs in Regulating Plaque Progression and Remodeling of Extracellular Matrix in Atherosclerosis. International Journal of Molecular Sciences, 2022. 23(22): p. 13731.
127. Fan, Z., S. Liu, and H. Zhou, LncRNA H19 regulates proliferation, apoptosis and ECM degradation of aortic smooth muscle cells via miR-1-3p/ADAM10 axis in thoracic aortic aneurysm. Biochemical Genetics, 2022. 60(2): p. 790-806.
128. Li, X., et al., Targeting non-coding RNAs in unstable atherosclerotic plaques: Mechanism, regulation, possibilities, and limitations. International Journal of Biological Sciences, 2021. 17(13): p. 3413.
129. Feng, F., et al., Role of Long Noncoding RNAs in the Regulation of Cellular Immune Response and Inflammatory Diseases. Cells, 2022. 11(22): p. 3642.
130. Holdt, L.M., et al., ANRIL expression is associated with atherosclerosis risk at chromosome 9p21. Arteriosclerosis, thrombosis, and vascular biology, 2010. 30(3): p. 620-627.
131. Song, C.-L., et al., Effect of circular ANRIL on the inflammatory response of vascular endothelial cells in a rat model of coronary atherosclerosis. Cellular Physiology and Biochemistry, 2017. 42(3): p. 1202-1212.
132. Chen, L., et al., ANRIL and atherosclerosis. Journal of Clinical Pharmacy and Therapeutics, 2020. 45(2): p. 240-248.
133. Li, P., et al., Inhibition of long noncoding RNA HIF1A-AS2 confers protection against atherosclerosis via ATF2 downregulation. Journal of advanced research, 2020. 26: p. 123-135.
134. Bian, W., et al., Downregulation of LncRNA NORAD promotes Ox-LDL-induced vascular endothelial cell injury and atherosclerosis. Aging (Albany NY), 2020. 12(7): p. 6385.
135. Pu, Z., J. Lu, and X. Yang, Emerging roles of circular RNAs in vascular smooth muscle cell dysfunction. Frontiers in Genetics, 2022. 12: p. 2639.
136. Cao, Q., et al., Circular RNAs in the pathogenesis of atherosclerosis. Life sciences, 2020. 255: p. 117837.
137. Holdt, L.M., et al., Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans. Nature communications, 2016. 7(1): p. 12429.
138. Zhang, X., et al., CircRNA RSF1 regulated ox-LDL induced vascular endothelial cells proliferation, apoptosis and inflammation through modulating miR-135b-5p/HDAC1 axis in atherosclerosis. Biological Research, 2021. 54.
139. Du, N., M. Li, and D. Yang, Hsa_circRNA_102541 regulates the development of atherosclerosis by targeting miR-296-5p/PLK1 pathway. Irish Journal of Medical Science (1971-), 2021: p. 1-7.
140. Zhang, Y., Y. Cao, and C. Liu, Autophagy and ischemic stroke. Autophagy: Biology and Diseases: Clinical Science, 2020: p. 111-134.
141. Ojaghihaghighi, S., et al., Comparison of neurological clinical manifestation in patients with hemorrhagic and ischemic stroke. World journal of emergency medicine, 2017. 8(1): p. 34.
142. Xiang, Y., et al., LncRNA MEG3 targeting miR-424-5p via MAPK signaling pathway mediates neuronal apoptosis in ischemic stroke. Aging (Albany NY), 2020. 12(4): p. 3156.
143. Guo, D., et al., Down-regulation of Lncrna MALAT1 attenuates neuronal cell death through suppressing Beclin1-dependent autophagy by regulating Mir-30a in cerebral ischemic stroke. Cellular Physiology and Biochemistry, 2017. 43(1): p. 182-194.
144. Chen, J., et al., Long non‑coding RNA MALAT1 serves as an independent predictive biomarker for the diagnosis, severity and prognosis of patients with sepsis. Molecular Medicine Reports, 2020. 21(3): p. 1365-1373.
145. Cao, D.-w., et al., The lncRNA Malat1 functions as a ceRNA to contribute to berberine-mediated inhibition of HMGB1 by sponging miR-181c-5p in poststroke inflammation. Acta Pharmacologica Sinica, 2020. 41(1): p. 22-33.
146. Yang, J., et al., LncRNAs a new target for post-stroke recovery. Current Pharmaceutical Design, 2020. 26(26): p. 3115-3121.
147. Gan, L., et al., Long noncoding RNA H19 mediates neural stem/progenitor cells proliferation, differentiation and apoptosis through the p53 signaling pathway after ischemic stroke. Biochemical and Biophysical Research Communications, 2022. 597: p. 8-15.
148. Fan, J., et al., LncRNAs stand as potent biomarkers and therapeutic targets for stroke. Frontiers in aging neuroscience, 2020. 12: p. 594571.
149. Jin, F., et al., Transcriptome-wide analysis to identify the inflammatory role of lncRNA Neat1 in experimental ischemic stroke. Journal of inflammation research, 2021. 14: p. 2667.
150. Chen, M., et al., Long non-coding RNAs and circular RNAs: insights into microglia and astrocyte mediated neurological diseases. Frontiers in Molecular Neuroscience, 2021. 14: p. 745066.
151. Bao, M.-H., et al., Long non-coding RNAs in ischemic stroke. Cell death & disease, 2018. 9(3): p. 281.
152. Shen, L., et al., Non-coding RNA and neuroinflammation: implications for the therapy of stroke. Stroke and Vascular Neurology, 2019. 4(2).
153. Wu, F., et al., Circular RNA TLK1 aggravates neuronal injury and neurological deficits after ischemic stroke via miR-335-3p/TIPARP. Journal of Neuroscience, 2019. 39(37): p. 7369-7393.
154. Chen, W., et al., Overexpression of circRNA circUCK2 attenuates cell apoptosis in cerebral ischemia-reperfusion injury via miR-125b-5p/GDF11 signaling. Molecular Therapy-Nucleic Acids, 2020. 22: p. 673-683.
155. Yang, L., et al., Extracellular vesicle–mediated delivery of circular RNA SCMH1 promotes functional recovery in rodent and nonhuman primate ischemic stroke models. Circulation, 2020. 142(6): p. 556-574.
156. Dai, Q., et al., Downregulation of circular RNA HECTD1 induces neuroprotection against ischemic stroke through the microRNA-133b/TRAF3 pathway. Life Sciences, 2021. 264: p. 118626.
157. Han, B., et al., Novel insight into circular RNA HECTD1 in astrocyte activation via autophagy by targeting MIR142-TIPARP: implications for cerebral ischemic stroke. Autophagy, 2018. 14(7): p. 1164-1184.
158. Zhou, D., et al., Circular RNA 0025984 ameliorates ischemic stroke injury and protects astrocytes through miR-143-3p/TET1/ORP150 pathway. Molecular Neurobiology, 2021. 58(11): p. 5937-5953.
159. Ma, Z., et al., The Construction and Analysis of Immune Infiltration and Competing Endogenous RNA Network in Acute Ischemic Stroke. Frontiers in Aging Neuroscience, 2022.
160. Humphrey, J. and C. Taylor, Intracranial and abdominal aortic aneurysms: similarities, differences, and need for a new class of computational models. Annu. Rev. Biomed. Eng., 2008. 10: p. 221-246.
161. Annambhotla, S., et al., Recent advances in molecular mechanisms of abdominal aortic aneurysm formation. World journal of surgery, 2008. 32: p. 976-986.
162. Peshkova, I.O., G. Schaefer, and E.K. Koltsova, Atherosclerosis and aortic aneurysm–is inflammation a common denominator? The FEBS journal, 2016. 283(9): p. 1636-1652.
163. Spin, J.M., et al., Non-coding RNAs in aneurysmal aortopathy. Vascular Pharmacology, 2019. 114: p. 110-121.
164. Man, H. and W. Bi, Expression of a novel long noncoding RNA (lncRNA), GASL1, is downregulated in patients with intracranial aneurysms and regulates the proliferation of vascular smooth muscle cells in vitro. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 2019. 25: p. 1133.
165. Wu, Z.-y., et al., Long noncoding RNAs in key cellular processes involved in aortic aneurysms. Atherosclerosis, 2020. 292: p. 112-118.
166. Rikhtegar, R., et al., Non-coding RNAs role in intracranial aneurysm: general principles with focus on inflammation. Life sciences, 2021. 278: p. 119617.
167. Cai, B., et al., STAT3-induced up-regulation of lncRNA NEAT1 as a ceRNA facilitates abdominal aortic aneurysm formation by elevating TULP3. Bioscience reports, 2020. 40(1).
168. Zhou, H., et al., Long noncoding RNAs in pathological cardiac remodeling: a review of the update literature. BioMed research international, 2019. 2019.
169. Penn, D.L., et al., The role of vascular remodeling and inflammation in the pathogenesis of intracranial aneurysms. Journal of clinical neuroscience, 2014. 21(1): p. 28-32.
170. Chalouhi, N., et al., Biology of intracranial aneurysms: role of inflammation. Journal of Cerebral Blood Flow & Metabolism, 2012. 32(9): p. 1659-1676.
171. Ding, X., et al., CircRNA DOCK1 Regulates miR-409-3p/MCL1 Axis to Modulate Proliferation and Apoptosis of Human Brain Vascular Smooth Muscle Cells. Frontiers in Cell and Developmental Biology, 2021. 9: p. 655628.
172. Yin, K. and X. Liu, Circ_0020397 regulates the viability of vascular smooth muscle cells by up-regulating GREM1 expression via miR-502-5p in intracranial aneurysm. Life Sciences, 2021. 265: p. 118800.
173. Teng, L., et al., Circular RNA hsa_circ_0021001 in peripheral blood: a potential novel biomarker in the screening of intracranial aneurysm. Oncotarget, 2017. 8(63): p. 107125.
174. Zhang, Z., et al., CircRNA_0079586 and circRNA_RanGAP1 are involved in the pathogenesis of intracranial aneurysms rupture by regulating the expression of MPO. Scientific Reports, 2021. 11(1): p. 19800.
175. Schaufelberger, M., Cardiomyopathy and pregnancy. Heart, 2019. 105(20): p. 1543-1551.
176. Hughes, S.E. and W.J. McKenna, New insights into the pathology of inherited cardiomyopathy. Heart, 2005. 91(2): p. 257-264.
177. Lee, T.M., et al., Pediatric cardiomyopathies. Circulation research, 2017. 121(7): p. 855-873.
178. Schultheiss, H.-P., et al., Dilated cardiomyopathy. Nature reviews Disease primers, 2019. 5(1): p. 32.
179. Yang, C., Y. Zhang, and B. Yang, MIAT, a potent CVD-promoting lncRNA. Cellular and Molecular Life Sciences, 2022. 79(1): p. 43.
180. Zhang, Y., et al., The long non-coding RNA H19 promotes cardiomyocyte apoptosis in dilated cardiomyopathy. Oncotarget, 2017. 8(17): p. 28588.
181. Gao, J., et al., The role and molecular mechanism of non-coding RNAs in pathological cardiac remodeling. International journal of molecular sciences, 2017. 18(3): p. 608.
182. Klattenhoff, C.A., et al., Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. Cell, 2013. 152(3): p. 570-583.
183. Xie, L., et al., The roles of lncRNA in myocardial infarction: molecular mechanisms, diagnosis biomarkers, and therapeutic perspectives. Frontiers in cell and developmental biology, 2021. 9: p. 680713.
184. Yang, L., et al., Ablation of lncRNA Miat attenuates pathological hypertrophy and heart failure. Theranostics, 2021. 11(16): p. 7995-8007.
185. Zhou, X., et al., lncRNA MIAT functions as a competing endogenous RNA to upregulate DAPK2 by sponging miR-22-3p in diabetic cardiomyopathy. Cell death & disease, 2017. 8(7): p. e2929-e2929.
186. Yu, Z., et al., CircRNAs open a new era in the study of cardiovascular disease. International Journal of Molecular Medicine, 2021. 47(1): p. 49-64.
187. Guo, Q., et al., Comprehensive construction of a circular RNA-associated competing endogenous RNA network identified novel circular RNAs in hypertrophic cardiomyopathy by integrated analysis. Frontiers in genetics, 2020. 11: p. 764.
188. Li, H., et al., Circular RNA circRNA_000203 aggravates cardiac hypertrophy via suppressing miR-26b-5p and miR-140-3p binding to Gata4. Cardiovascular research, 2020. 116(7): p. 1323-1334.
189. Zhao, Q., et al., CircRNA 010567 plays a significant role in myocardial infarction via the regulation of the miRNA-141/DAPK1 axis. Journal of Thoracic Disease, 2021. 13(4): p. 2447.
190. Jin, L., et al., Circular RNA Rbms1 inhibited the development of myocardial ischemia reperfusion injury by regulating miR-92a/BCL2L11 signaling pathway. Bioengineered, 2022. 13(2): p. 3082-3092.
191. Gan, J., et al., Circular RNA_101237 mediates anoxia/reoxygenation injury by targeting let‑7a‑5p/IGF2BP3 in cardiomyocytes. International Journal of Molecular Medicine, 2020. 45(2): p. 451-460.
192. Doctor, N.S., et al., Acute pericarditis. Progress in cardiovascular diseases, 2017. 59(4): p. 349-359.
193. Aghagoli, G., et al., Cardiac involvement in COVID‐19 patients: Risk factors, predictors, and complications: A review. Journal of cardiac surgery, 2020. 35(6): p. 1302-1305.
194. Babapoor-Farrokhran, S., et al., Arrhythmia in COVID-19. SN Comprehensive Clinical Medicine, 2020. 2: p. 1430-1435.
195. Caforio, A.L., et al., Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European heart journal, 2013. 34(33): p. 2636-2648.
196. Fang, Q., et al., LncRNA TUG1 alleviates cardiac hypertrophy by targeting miR‐34a/DKK1/Wnt‐β‐catenin signalling. Journal of Cellular and Molecular Medicine, 2020. 24(6): p. 3678-3691.
197. Tikhomirov, R., et al., Exosomes: from potential culprits to new therapeutic promise in the setting of cardiac fibrosis. Cells, 2020. 9(3): p. 592.
198. Li, J., et al., Circular RNAs: Biogenesis, Biological Functions, and Roles in Myocardial Infarction. International Journal of Molecular Sciences, 2023. 24(4): p. 4233.
199. da Silva, A.M.G., et al., Long non-coding RNA and circular RNA: new perspectives for molecular pathophysiology of atrial fibrillation. Molecular Biology Reports, 2023: p. 1-11.
